{"schema_version":"1","generated_at":"2026-11-21T16:16:29.698Z","data_as_of":null,"url":"https://www.findmykol.com/kol/daron-street","json_url":"https://www.findmykol.com/kol/daron-street/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"daron-street","name":"Daron Street","credential":"MD","specialty":"Gynecologic Oncology","specialty_raw":"Gynecologic Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Oklahoma Cancer Specialists and Research Institute","institution_url":"https://www.findmykol.com/institution/oklahoma-cancer-specialists-and-research-institute","city":"Tulsa","state":"OK","region":{"label":"South Central","url":"https://www.findmykol.com/region/south-central"}},"identifiers":{"on_file":["npi","openalex"],"values":"Shown on the profile page to a signed-in account."},"summary":"Daron Street is an Oncology physician affiliated with Oklahoma Cancer Specialists and Research Institute. OpenAlex indexes 15 publications with 481 citations (h-index 10).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":15,"cited_by_count":481,"h_index":10,"latest_activity_year":2025,"source":"works"},"payments":{"company_count":51,"program_years":{"first":2021,"last":null},"rows_total":91,"shown":3,"withheld":88,"rows":[{"payer":"INTUITIVE SURGICAL, INC.","program_year":2025,"amount_usd":4000,"payment_count":1},{"payer":"E.R. Squibb & Sons, L.L.C.","program_year":2025,"amount_usd":2275,"payment_count":1},{"payer":"BeOne Medicines USA, Inc.","program_year":2025,"amount_usd":304.96,"payment_count":4}],"source":"payments"},"prescribing":{"data_year":2023,"areas_total":10,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":40.9,"classes_total":5,"classes":[{"class":"Platinum-based Drug","setting":"administered","share_pct":16.2,"drugs":[{"name":"Oxaliplatin","share_pct":97.9},{"name":"Carboplatin","share_pct":2.1}],"max_beneficiaries":18},{"class":"PD-1 inhibitor","setting":"administered","share_pct":14.7,"drugs":[{"name":"Pembrolizumab","share_pct":100}],"max_beneficiaries":17}]},{"area":"Blood & clotting","share_pct":35.1,"classes_total":2,"classes":[{"class":"Iron, parenteral preparations","setting":"administered","share_pct":35.1,"drugs":[{"name":"Ferric carboxymaltose","share_pct":100}],"max_beneficiaries":21},{"class":"Factor Xa inhibitor","setting":"prescribed","share_pct":0,"drugs":[{"name":"Eliquis","share_pct":100}],"max_beneficiaries":null}]},{"area":"Metabolism & gastrointestinal","share_pct":19,"classes_total":2,"classes":[{"class":"Serotonin-3 Receptor Antagonist","setting":"mixed","share_pct":10,"drugs":[{"name":"Granisetron","share_pct":91},{"name":"Palonosetron hcl","share_pct":6.7},{"name":"Ondansetron hydrochloride","share_pct":2},{"name":"Ondansetron Hcl","share_pct":0.4}],"max_beneficiaries":34},{"class":"Substance P/Neurokinin-1 Receptor Antagonist","setting":"administered","share_pct":9,"drugs":[{"name":"Aprepitant","share_pct":100}],"max_beneficiaries":24}]}],"care_setting":{"dominant":"office","data_year":2023,"office_pct":100,"facility_pct":0},"source":"medicare"},"publications":{"total":15,"shown":5,"withheld":10,"matched_by":"OpenAlex author record","recent":[{"title":"Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005","year":2024,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.24.00683","status":"verified"},{"title":"A phase I/II study of maplirpacept in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer (OC): Phase 1 results.","year":2024,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2024.42.16_suppl.e17546","status":"verified"},{"title":"Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study","year":2022,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.22.00146","status":"verified"},{"title":"Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial","year":2019,"journal":"The Lancet Oncology","source_url":"https://doi.org/10.1016/s1470-2045(19)30178-0","status":"verified"},{"title":"A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study","year":2015,"journal":"Gynecologic Oncology","source_url":"https://doi.org/10.1016/j.ygyno.2015.04.005","status":"verified"}],"source":"works"},"similar":[{"name":"Katherine Moxley","slug":"katherine-moxley","institution":"Oklahoma Cancer Specialists and Research Institute","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/katherine-moxley","json_url":"https://www.findmykol.com/kol/katherine-moxley/profile.json"},{"name":"Janelle Pavlis","slug":"janelle-pavlis","institution":"Oklahoma Cancer Specialists and Research Institute","specialty":"Dermatology","url":"https://www.findmykol.com/kol/janelle-pavlis","json_url":"https://www.findmykol.com/kol/janelle-pavlis/profile.json"},{"name":"Paul Zito","slug":"paul-zito","institution":"Oklahoma Cancer Specialists and Research Institute","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/paul-zito","json_url":"https://www.findmykol.com/kol/paul-zito/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Stuart Orkin","slug":"stuart-orkin","institution":"Harvard Medical School","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/stuart-orkin","json_url":"https://www.findmykol.com/kol/stuart-orkin/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":88,"publications":10}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}